Details

Autor(en) / Beteiligte

• Oji, Yusuke
• Kagawa, Naoki
• Arita, Hideyuki
• Naka, Norifumi
• Hamada, Ken-Ichiro
• Outani, Hidetatsu
• Shintani, Yasushi
• Takeda, Yoshito
• Morii, Eiichi
• Shimazu, Kenzo
• Suzuki, Motoyuki
• Nishida, Sumiyuki
• Nakata, Jun
• Tsuboi, Akihiro
• Iwai, Miki
• Hayashi, Sae
• Imanishi, Rin
• Ikejima, Sayaka
• Kanegae, Mizuki
• Iwamoto, Masahiro
• Ikeda, Mayu
• Yagi, Kento
• Shimokado, Haruka
• Nakajima, Hiroko
• Hasegawa, Kana
• Morimoto, Soyoko
• Fujiki, Fumihiro
• Nagahara, Akira
• Tanemura, Atsushi
• Ueda, Yutaka
• Mizushima, Tsunekazu
• Ohmi, Masato
• Ishida, Takayuki
• Fujimoto, Manabu
• Nonomura, Norio
• Kimura, Tadashi
• Inohara, Hidenori
• Okada, Seiji
• Kishima, Haruhiko
• Hosen, Naoki
• Kumanogoh, Atsushi
• Oka, Yoshihiro
• Sugiyama, Haruo

Titel

WT1 Trio Peptide-Based Cancer Vaccine for Rare Cancers Expressing Shared Target WT1

Ist Teil von

• Cancers, 2023-01, Vol.15 (2), p.393

Ort / Verlag

Switzerland: MDPI AG

Erscheinungsjahr

2023

Quelle

EZB Electronic Journals Library

Beschreibungen/Notizen

• No standard treatment has been established for most rare cancers. Here, we report a clinical trial of a biweekly WT1 tri-peptide-based vaccine for recurrent or advanced rare cancers. Due to the insufficient number of patients available for a traditional clinical trial, the trial was designed for rare cancers expressing shared target molecule WT1. The recruitment criteria included WT1-expressing tumors as well as HLA-A*24:02 or 02:01. The primary endpoints were immunoglobulin G (IgG) antibody (Ab) production against the WT1-235 cytotoxic T lymphocyte (CTL) epitope and delayed-type hypersensitivity (DTH) skin reactions to targeted WT1 CTL epitopes. The secondary endpoints were safety and clinical efficacy. Forty-five patients received WT1 Trio, and 25 (55.6%) completed the 3-month protocol treatment. WT1-235 IgG Ab was positive in 88.0% of patients treated with WT1 Trio at 3 months, significantly higher than 62.5% of the weekly WT1-235 CTL peptide vaccine. The DTH positivity rate in WT1 Trio was 62.9%, which was not significantly different from 60.7% in the WT1-235 CTL peptide vaccine. The WT1 Trio safety was confirmed without severe treatment-related adverse events, except grade 3 myasthenia gravis-like symptoms observed in a patient with thymic cancer. Fifteen (33.3%) patients achieved stable disease after 3 months of treatment. In conclusion, the biweekly WT1 Trio vaccine containing the WT1-332 helper T lymphocyte peptide induced more robust immune responses targeting WT1 than the weekly WT1-235 CTL peptide vaccine. Therefore, WT1-targeted immunotherapy may be a potential therapeutic strategy for rare cancers.